leisure time -WSS

leisure time

author：entertainment 2025-10-01 02:13:21 - browse：13691

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Readout Newsletter: Geron, Novo Nordisk, WuXi updates

WSS

Physicians and social media: If you see something, say something?

SCOTUS questions limit to govt efforts to fight misinformation

A letter from the executive editor: The 2023 STATUS List

Readout Newsletter: Bluebird, CVS, Contineum

Argenx readies a blockbuster opportunity with drug for autoimmune disease

UnitedHealth increases loan offers after Change Healthcare outage

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Anesthesiologist group: stop taking Ozempic before surgery

Physicians and social media: If you see something, say something?

23andMe had bad news about my health. I wish a person had delivered it

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

Continuity nursing helped my family in our darkest PICU moments

Colonoscopy prep: Liquid

Activists slam private health insurers over coverage restrictions

UpToDate has a racism problem: Dr. Stanley Goldfarb

Apple is now the first public company to be valued at $3 trillion

Being 'nonadherent' patient made me a more empathetic doctor

hotspot

Skip the lead apron during X

Skip the lead apron during X

5 to watch: Tech startups trying to solve health care's staffing crisis

Orchard's therapy for neuron disease in children wins FDA approval

U.K. researchers warn about biases in medical devices, algorithms

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

focus

hotspot

knowledge

focus